Nanogroup

Nanogroup FCF Margin

The Free Cash Flow Margin of Nanogroup (NNG.WA) as of Oct 16, 2026 is -281,341.90 %. In the previous year, Free Cash Flow Margin was -239,570.78 % — a change of 17.44% (lower).

FCF Margin

-281,341.90 %

YoY

17.44%

Last updated:

Free Cash Flow Margin of Nanogroup is 2024 -281,341.90 % . Free Cash Flow Margin of Nanogroup was 2023 -239,570.78 % . It decreases by 17.44% lower compared to the previous year.

The Nanogroup FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2017
-28,717.50 PLN
Jan 1, 2018
-8,459.11 PLN
Jan 1, 2019
-1,249.65 PLN
Jan 1, 2020
-510.94 PLN
Jan 1, 2021
-1,435.55 PLN
Jan 1, 2022
-3,218.78 PLN
Jan 1, 2023
-239,570.78 PLN
Jan 1, 2024
-281,341.90 PLN
The Nanogroup FCF Margin history
YEARFCF MarginYoY
-281,341.90 %+17.44%
-239,570.78 %+7,342.90%
-3,218.78 %+124.22%
-1,435.55 %+180.97%
-510.94 %-59.11%
-1,249.65 %-85.23%
-8,459.11 %-70.54%
-28,717.50 %+1,585.84%
-1,703.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanogroup Stock analysis

What does Nanogroup do? Nanogroup SA is a company based in Warsaw, Poland, operating within the Health Care sector, specifically in Life Sciences Tools & Services. The company went public through an IPO on December 21, 2017, and is listed under the ticker NNG.WA with ISIN PLNNGRP00011. Nanogroup SA focuses on medical research and development, with a particular emphasis on biotechnological projects related to cancer prevention, early diagnosis, targeted cancer therapies, and ontological rehabilitation. The company's portfolio includes several projects: NanoVelos, which develops drug delivery systems for oncologic medicines to enhance their effectiveness; NanoSanguis, which works on artificial blood solutions to sustain patients with severe injuries; and NanoThea, which is dedicated to early-stage cancer detection technologies. Additionally, the company has a project named Organ Farm, aimed at preserving human organs outside the body. Nanogroup SA maintains a website at https://nanogroup.eu/ for further information. The company is headquartered in Warsaw, located in the Mazowieckie region of Poland. It operates within the life sciences industry, concentrating on innovative biotechnological solutions for healthcare applications. The company's activities are centered around advancing medical research through the development of specialized tools and services in the life sciences sector. No additional details about the company's founding year, specific personnel, or financial figures are provided in the source material. Nanogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanogroup stock

Free Cash Flow Margin of Nanogroup is -281,341.90 % in 2024.

Free Cash Flow Margin of Nanogroup changed from -239,570.78 % to -281,341.90 %, representing a 17.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Nanogroup since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Nanogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nanogroup

All Key Metrics — Nanogroup